Sorafenib: muscle wasting.
Sorafenib inhibits multiple kinases involved in angiogenesis and tumour growth. It is used for second-line treatment of advanced kidney cancer and some forms of liver cancer. A placebo-controlled trial in 80 patients with metastatic kidney cancer showed a statistically significant increase in muscle loss during sorafenib therapy. Skeletal muscle mass fell by about 5% after 6 months of treatment and by 8% after one year. In practice, patients treated with sorafenib should be assessed for muscle wasting. The clinical consequences of muscle wasting--loss of autonomy and walking difficulties--should be considered when weighing the benefits and harms of sorafenib therapy.
D001549:Benzamides; D001557:Benzenesulfonates / Q000009:adverse effects*; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles / Q000009:adverse effects; D018482:Muscle, Skeletal / Q000187:drug effects*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010879:Piperazines / Q000009:adverse effects; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects; D011758:Pyrroles / Q000009:adverse effects; D012206:Rhabdomyolysis / Q000139:chemically induced; D000077157:Sorafenib; D000077210:Sunitinib
D001549:Benzamides; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011743:Pyrimidines; D011758:Pyrroles; D009536:Niacinamide; D000068877:Imatinib Mesylate; D000077157:Sorafenib; D000077210:Sunitinib